Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus to the development of biologics and biosimilars. Over the last decade-plus, China has become a booming biopharma innovator thanks in part to a big boost from its government.Now the question is, can its neighbor to the south, India, make a similar advancement?Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with

Feb. 3, 2026 -- Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences' reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM™ Antimicrobial Technology platform to minimize wound care complications. "The strategic investment from BioLab Holdings marks a pivo

Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline. The financing includes a €20m strategic investment from Sanofi and €40m from existing and new investors such as Artal (advised by Invus), Redmile Group, Cormorant Asset Management, Sofinnova Partners, Sphera Healthcare, and Coastlands Capital. Settlement of the offering is expected around 30 January 2026, s

Jan. 28, 2026 -- Stellular Bio, the pioneer of Platelet-derived Regenerative Biologic (PRB) therapeutics, is pleased to announce the closing of its Series 1 financing round. Led by Ziff Capital Partners and joined by Cockrell Interests and others, the round will help advance Stellular's lead candidate, STLR-201, into clinical testing as a treatment for Sjogren's disease dry eye. Sjogren's disease (SjD) is a complex multisystem autoimmune disorder affecting roughly 4 million patients in the Uni

Proceeds support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells (“Tregs”) in inflammatory diseases affecting skin and other barrier tissues, including atopic dermatitis The single ascending dose portion of the ongoing Phase 1a/b clinical trial of TRB-061 has been completed, with the multiple ascending dose portion underway Financing also enables TRB-071 and TRB-081, two mechanistically distinct preclinical programs from

Jan. 27, 2026 -- Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has completed a second close of its Series C financing, raising an additional $24 million. Combined with additional available capital and non-dilutive funding, including multiple project agreements with the U.S. government, the company has secured more than $175 million over the past year. Proceeds from the financing will be used to expand Antheia's

Jan. 26, 2026 -- Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital. This close brings the total Series B raise to $23.3 million. These funds will be used to support the further clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll

Jan. 22, 2026 -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ: MDT) (Medtronic), the world’s largest medical technology company. The investment closed immediately following Anteris’ underwritten

Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies. Corxel Pharmaceuticals has brought in $287 million from its series D1 fundraising push, giving it enough money to advance its oral GLP-1 drug CX11, among other pipeline candidates. In particular, Corxel, which has offices in New Jersey, Hong Kong, Shanghai and Beijing, will use the proceeds to complete Phase II testing for CX11

Think Bioscience has raised a $55 million Series A led by investors including Regeneron Ventures, Innovation Endeavors and Janus Henderson. The University of Colorado spinout is crafting small molecules aimed at difficult-to-drug targets. While many so-called “undruggable” startups have focused on cancer, Think Bio is developing a treatment for a genetic disease called Noonan syndrome, which it says impacts around one in 2,500 births and can lead to a wide set of symptoms, including heart probl